Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 5, Issue 6

First report of a carbapenemase OXA-48-producing clinical isolate Open Access

Abstract

Carbapenems are usually used in the treatment of infections caused by cephalosporin-resistant ; however, the increase in carbapenem-resistant (CRE) has become one of the most important problems in public health. is associated with intestinal and extraintestinal infections, especially in patients with any chronic disease or some type of immunosupression. is resistant to first-generation aminopenicillins and cephalosporins owing to the β-lactamase (Amp C) in their chromosome; the only carbapenem-resistant strain described until now was due to a lack of the OmpK36 protein that plays an important role in permeability to carbapenems.

We present the case of a 65-year-old male diagnosed with acute lithiasic cholecystitis. Culture of the biliary prosthesis yielded a OXA-48-producing that was identified by MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) MS. Carbapenemase production was detected by immunochromatography and confirmed by sequencing.

To our knowledge, this is the first report of OXA-48-producing probably obtained by horizontal transfer from OXA-48 isolated in previous samples.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): carbapenem , carbapenemase , Hafnia alvei and OXA-48
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000498.v3
2023-06-22
2026-02-16

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/5/6/acmi000498.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000498.v3&mimeType=html&fmt=ahah

References

  1. Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 2015; 5:61 [View Article] [PubMed]
     [Google Scholar]
  2. Maurer FP, Castelberg C, Quiblier C, Bloemberg GV, Hombach M. Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm. J Clin Microbiol 2015; 53:95–104 [View Article] [PubMed]
     [Google Scholar]
  3. Katchanov J, Asar L, Klupp E-M, Both A, Rothe C et al. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. PLoS One 2018; 13:e0195757 [View Article] [PubMed]
     [Google Scholar]
  4. Sánchez-López J, Cantón R. Current status of ESKAPE microorganisms in Spain: epidemiology and resistance phenotypes. Rev Esp Quimioter 2019; 32 Suppl 2:27–31 [PubMed]
     [Google Scholar]
  5. Ramos-Vivas J. Microbiología de Hafnia alvei. Enferm Infecc Microbiol Clín 2020; 38:1–6 [View Article] [PubMed]
     [Google Scholar]
  6. Rodríguez-Guardado A, Boga JA, Diego ID, Ordás J, Alvarez ME et al. Clinical characteristics of nosocomial and community-acquired extraintestinal infections caused by Hafnia alvei. Scand J Infect Dis 2005; 37:870–872 [View Article] [PubMed]
     [Google Scholar]
  7. Günthard H, Pennekamp A. Clinical significance of extraintestinal Hafnia alvei isolates from 61 patients and review of the literature. Clin Infect Dis 1996; 22:1040–1045 [View Article] [PubMed]
     [Google Scholar]
  8. Moreno MC, Troncoso VM, Coria De La HP, Ledermann DW, Del Valle MG et al. Reporte de cuatro casos clínicos de bacteriemia por Hafnia alvei en una unidad cardio-quirúrgica pediátrica. Rev Chil Infectol 2010; 27:40–44 [View Article]
     [Google Scholar]
  9. Millán Rodríguez MR, Muñoz Pérez MA, Meseguer Frutos MD, Cano Sánchez A, Román López Andreu F et al. Neumonía nosocomial por Hafnia alvei. An Med Interna 2003; 20:595–596 [View Article]
     [Google Scholar]
  10. Stanic M, Meusburger E, Hartmann G, Lhotta K. Hafnia alvei Urosepsis in a Kidney Transplant Patient. Case Rep Transpl 2015; 2015:863131 [View Article] [PubMed]
     [Google Scholar]
  11. Litrenta J, Oetgen M. Hafnia alvei: a new pathogen in open fractures. Trauma Case Reports 2017; 8:41–45 [View Article]
     [Google Scholar]
  12. Suárez T, Vega J, Vega R, Acosta Y. Infective endocarditis in native mitral valve by Hafnia alvei. Revista Cubana de Medicina Militar 2018; 47:80–87
     [Google Scholar]
  13. Yarlagadda K, Shrimanker I, Nookala VK. Catheter-associated Hafnia alvei-induced Urosepsis. Cureus 2019; 11:e6471 [View Article] [PubMed]
     [Google Scholar]
  14. Skurnik D, Nucci A, Ruimy R, Lasocki S, Muller-Serieys C et al. Emergence of carbapenem-resistant Hafnia: the fall of the last soldier. Clin Infect Dis 2010; 50:1429–1431 [View Article] [PubMed]
     [Google Scholar]
  15. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters version 10.0; 2020 www.eucast.org/clinical_breakpoints/
  16. Cardile AP, Forbes D, Cirigliano V, Stout B, Das NP et al. Hafnia alvei pyelonephritis in a renal transplant recipient: case report and review of an under-recognized nosocomial pathogen. Transpl Infect Dis 2011; 13:407–410 [View Article] [PubMed]
     [Google Scholar]
  17. Heras M, Sánchez R, Fernández-Reyes MJ, Hernando S. Sepsis por Hafnia alvei en una paciente con trasplante renal. Nefrología 2008; 28:470–471
     [Google Scholar]
  18. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 2019; 69:S565–S575 [View Article] [PubMed]
     [Google Scholar]
  19. Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An update on eight “New” antibiotics against multidrug-resistant Gram-negative bacteria. J Clin Med 2021; 10:1068 [View Article] [PubMed]
     [Google Scholar]
  20. Suay-García B, Pérez-Gracia MT. Present and future of Carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics 2019; 8:122 [View Article] [PubMed]
     [Google Scholar]
  21. Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 2019; 25:943–950 [View Article] [PubMed]
     [Google Scholar]
  22. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597–1606 [View Article] [PubMed]
     [Google Scholar]
  23. Göttig S, Gruber TM, Stecher B, Wichelhaus TA, Kempf VAJ. In vivo horizontal gene transfer of the carbapenemase OXA-48 during a nosocomial outbreak. Clin Infect Dis 2015; 60:1808–1815 [View Article] [PubMed]
     [Google Scholar]
  24. Hidalgo L, de Been M, Rogers MRC, Schürch AC, Scharringa J et al. Sequence-based epidemiology of an OXA-48 plasmid during a hospital outbreak. Antimicrob Agents Chemother 2019; 63:e01204-19 [View Article] [PubMed]
     [Google Scholar]
  25. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH et al. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 2020; 34:e00115-20 [View Article] [PubMed]
     [Google Scholar]
  26. Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE et al. Current promising antibiotics and future approaches in combating carbapenemase-producing Enterobacteriaceae. Proc Int Conf Automot User Interfaces Interact Veh Appl 2020; 66:25
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000498.v3
Loading
First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate
Access Microbiology 5, 000498.v3 (2023); https://doi.org/10.1099/acmi.0.000498.v3
/content/journal/acmi/10.1099/acmi.0.000498.v3
/content/journal/acmi/10.1099/acmi.0.000498.v3
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error